Biogen and Ionis See Boost From Clinical Drug Trial

Shares of Biogen (BIIB) - Get Report and Ionis Pharmaceuticals (IONS) - Get Report were higher Monday after announcing that their treatment for a rare, children's spine disorder had some positive results. The two companies said their treatment for infantile-onset spinal muscular atrophy demonstrated statistically significant improvement in certain motor functions, according to a Wall Street Journal report. Ionis shares jumped nearly 30 percent on the news. Biogen plans to submit for regulatory approval in the coming months.